Home › Funds › Avoro Capital Advisors LLC › XENE

Avoro Capital Advisors LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

Avoro Capital Advisors LLC reported holding 5,500,000 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$204.5M, representing 2.12% of its reported portfolio and ranking #12 among its reported holdings. Avoro Capital Advisors LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)5.50M sh
Reported value held$204.54M
Portfolio Weight2.12%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Avoro Capital Advisors LLC's XENE position evolved

Avoro Capital Advisors LLC first disclosed a stake in XENE in Q3 2023 at 4,900,000 shares (US$167.4M). The position peaked in Q2 2026 at 5,777,777 shares, worth US$348.7M. Across 13 filings, Avoro Capital Advisors LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 5,500,000 shares valued at US$204.5M — a reduction of -277,777 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.90M $167.38M New
Q4 2023 5.67M $261.01M Add
Q1 2024 5.67M $243.95M Hold
Q2 2024 5.67M $220.94M Hold
Q3 2024 5.67M $223.10M Hold
Q4 2024 5.67M $222.13M Hold
Q1 2025 5.74M $192.63M Add
Q2 2025 5.40M $169.02M Reduce
Q3 2025 5.40M $216.81M Hold
Q4 2025 5.42M $243.12M Hold
Q1 2026 5.78M $335.98M Add
Q2 2026 5.78M $348.75M Hold
Q3 2026 5.50M $204.54M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in XENE — the largest reported positions include DRIEHAUS CAPITAL MANAGEMENT LLC (US$132.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$97.5M), Affinity Asset Advisors, LLC (US$70.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Avoro Capital Advisors LLC held XENE?

Avoro Capital Advisors LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Avoro Capital Advisors LLC's current position in XENE?

As of Q3 2026, Avoro Capital Advisors LLC holds 5.50M shares of XENE (XENON PHARMACEUTICALS INC), valued at $204.54M, representing 2.12% of its reported portfolio and ranking #12.

Has Avoro Capital Advisors LLC been buying or selling XENE?

In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC reduced its position in XENE. The position peaked in Q2 2026 at 5.78M shares.

Which other funds hold XENE?

Other major institutional holders of XENE include DRIEHAUS CAPITAL MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P., Affinity Asset Advisors, LLC, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.